How Has NASP Advocated on Behalf of Specialty Pharmacies in the Fight Against DIR Fees?


 
Arquette: NASP has been very actively engaged in working with members of congress, in working with CMS, also working with the members of the members of the organization and the public to showcase and to highlight the problem with DIR fees and how it’s impacting specialty pharmacies ability to continue to provide care for Medicare part D beneficiaries.

This year we also launched a StopDIRfees.com website, which has a great instructional video, which helps to kind of bring down the complexity of the issue into a way that folks can understand and wrap their arms around, and just have a better understanding of what is happening and why it can be so detrimental to our industry.

Most Popular

Related Articles

In this video, Gordon Vanscoy, PharmD, MBA, CEO of PANTHERx, describes the methods of patient support used by PantheRx throughout treatment to provide optimal care.
Dallas-based Senderra Rx achieves perfect net promoter score.
Top news of the week from Specialty Pharmacy Times.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$